



Metro Medical

DSCSA: FDA Exemption from DSCSA Requirements for Eligible Trading Partners

On October 9, 2024, the FDA issued an exemption from the DSCSA Enhanced Drug Distribution Security requirements for *eligible* trading partners. This exemption is part of the agency's broader efforts to avoid supply chain disruptions and ensure patients will not face delays in receiving the medicines they need, while continuing progress towards full implementation of DSCSA.

Per the FDA "eligible trading partners, are trading partners who have successfully completed or made documented efforts to complete data connections with their immediate trading partners, but still face challenges exchanging data."

The exemption duration varies depending on the eligible trading partners:

- Manufacturers and Repackagers: May 27, 2025
- Wholesale Distributors: August 27, 2025
- Dispensers with 26 or more full-time employees: November 27, 2025

Cardinal Health is committed to continuing efforts to implement necessary measures to satisfy the DSCSA enhanced drug distribution security requirements and we are working with our suppliers to successfully receive accurate serialized data. We will share more about how this exemption will impact customers in the coming weeks.

For additional information on the FDA exemption, please see the official announcement: [Waivers and Exemptions Beyond the Stabilization Period | FDA](#).

Upcoming

Be prepared for the new Metro Returns and Exceptions process. More information will be forthcoming in November 2024.



For additional DSCSA information, please see the [FDA website](#) and the Cardinal Health [Pharmaceutical Tracing for Pharmacies website](#).

If you have additional questions, please contact your Cardinal Health representative or email dscsainfo@cardinalhealth.com.